CIBACEN

This brand name is authorized in Germany, Italy, Japan, Netherlands, Spain, Turkey.

Active ingredients

The drug CIBACEN contains one active pharmaceutical ingredient (API):

1	Benazepril UNII N1SN99T69T - BENAZEPRIL HYDROCHLORIDE
	Benazepril is a prodrug which, after hydrolysis to the active substance benazeprilat, inhibits the angiotensin-converting enzyme (ACE) and so blocks the conversion of angiotensin I to angiotensin II. This reduces all the effects mediated by angiotensin II – i.e. vasoconstriction and production of aldosterone, which promotes the reabsorption of sodium and water in the renal tubules – and elevates cardiac output.
	Read more about Benazepril

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09AA07	Benazepril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	04511447, 04511476, 04511482, 04511507, 04511513, 04511542
ES	Centro de información online de medicamentos de la AEMPS	59551, 59552, 59553
IT	Agenzia del Farmaco	027516020, 027516032
JP	医薬品医療機器総合機構	2144007F1027, 2144007F2023, 2144007F3020
NL	Z-Index G-Standaard, PRK	36218
TR	İlaç ve Tıbbi Cihaz Kurumu	8698856090065